Kevin Yau

@KevinYauMD

Nephrologist, University of Toronto

Toronto, Ontario Joined June 2020

315 Following 275 Followers 217 Posts

Latest posts 5

Kevin Yau @KevinYauMD Dec 16, 2022

Our experience with a dramatic drug rash associated with Empagliflozin use. We were worried it was vasculitis at first!

CMAJ @CMAJ Dec 16, 2022

Drug eruption:
A man with congestive heart failure, atrial fibrillation, chronic kidney disease and hypothyroidism presented with a painful, bilateral, nonblanching rash 2 weeks after starting empagliflozin ➡️ cmaj.ca/lookup/doi/10.…
@KevinYauMD @bourneauguste @UofTNephrology

View quoted post on X

Kevin Yau @KevinYauMD Jul 20, 2022

Happy to share our review on some practical things to consider when prescribing SGLT2 inhibitors and who to give them to! @atit_dharia @UofTNephrology

KIReports @KIReports Jul 20, 2022

Prescribing SGLT2 Inhibitors in Patients With #CKD: Expanding Indications and Practical Considerations

doi.org/10.1016/j.ekir…

#KIRReview

View quoted post on X

Kevin Yau @KevinYauMD Feb 4, 2022

💉Our study in dialysis patients receiving #COVID-19 vaccines is out in @CMAJ showing higher antibody levels with Moderna compared to Pfizer cmaj.ca/content/early/… @hladunewich @gingraslab1 @UofTNephrology @UHN_Research @Sunnybrook @COVIDimmunityTF @ChrisChanUHN @PD_Perls 🧵 1/

Kevin Yau @KevinYauMD Sep 5, 2021

Glad to share that our study showing poor antibody response to a single COVID-19 vaccine dose in hemodialysis patients is finally out! @PD_Perls @ChrisChanUHN @gingraslab1 @COVIDimmunityTF @UofTNephrology @Sunnybrook

JAMA Network Open @JAMANetworkOpen Sep 2, 2021

A study in dialysis patients receiving the BNT162b2 vaccine found that patients receiving one dose, 6% had Anti-RBD above convalescent serum levels compared to 41% receiving two doses, cautioning against delaying the second dose in this population. ja.ma/3gX3HFb
View quoted post on X

Kevin Yau @KevinYauMD Jun 13, 2021

A great summary of our preprint on the poor antibody response to a single dose of the Pfizer vaccine in hemodialysis patients.

gingraslab @gingraslab1 Jun 9, 2021

Good summary by @COVIDimmunityTF of the study by @mhladunewich for which we and @nbcc_ltri did antibody measurements:
"Poor antibody response to the Pfizer-BioNTech vaccine for patients with chronic kidney disease" covid19immunitytaskforce.ca/poor-antibody-….
Preprint: medrxiv.org/content/10.110…
View quoted post on X